Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10297MR)

This product GTTS-WQ10297MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10297MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14812MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ2441MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ1160MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ6770MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ6097MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ8804MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ1717MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ12278MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW